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A B S T R A C T
Background
Evidence suggests that many perimenopausal and early postmenopausal women will experience menopausal symptoms; hot flushes are
themost common. Symptoms caused by fluctuating levels of oestrogenmay be alleviated by hormone therapy (HT), but amarked global
decline in its use has resulted from concerns about the risks and benefits of HT. Consequently, many women are seeking alternatives.
As large numbers of women are choosing not to take HT, it is increasingly important to identify evidence-based lifestyle modifications
that have the potential to reduce vasomotor menopausal symptoms.
Objectives
To examine the effectiveness of any type of exercise intervention in the management of vasomotor symptoms in symptomatic peri-
menopausal and postmenopausal women.
Search methods
Searches of the following electronic bibliographic databases were performed to identify randomised controlled trials (RCTs): Cochrane
Menstrual Disorders and SubfertilityGroup Specialised Trials Register, theCochrane Central Register of Controlled Trials (CENTRAL)
(Wiley Internet interface), MEDLINE (Ovid), EMBASE (Ovid), PsycINFO (Ovid), the Science Citation Index and the Social Science
Citation Index (Web of Science), the Cumulative Index toNursing and AlliedHealth Literature (CINAHL) (Ovid) and SPORTDiscus.
Searches include findings up to 3 March 2014.
Selection criteria
RCTs in which any type of exercise intervention was compared with no treatment/control or other treatments in the management of
menopausal vasomotor symptoms in symptomatic perimenopausal/postmenopausal women.
Data collection and analysis
Five studies were deemed eligible for inclusion. Two review authors independently selected the studies, and three review authors
independently extracted the data. The primary review outcome was vasomotor symptoms, defined as hot flushes and/or night sweats.
We combined data to calculate standardised mean differences (SMDs) with 95% confidence intervals (CIs). Statistical heterogeneity
was assessed using the I2 statistic. We assessed the overall quality of the evidence for main comparisons using GRADE (Grades of
Recommendation, Assessment, Development and Evaluation) methods.
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Main results
We included five RCTs (733 women) comparing exercise with no active treatment, exercise with yoga and exercise with HT. The
evidence was of low quality: Limitations in study design were noted, along with inconsistency and imprecision. In the comparison of
exercise versus no active treatment (three studies, n = 454 women), no evidence was found of a difference between groups in frequency
or intensity of vasomotor symptoms (SMD -0.10, 95% CI -0.33 to 0.13, three RCTs, 454 women, I2 = 30%, low-quality evidence).
Nor was any evidence found of a difference between groups in the frequency or intensity of vasomotor symptoms when exercise was
compared with yoga (SMD -0.03, 95% CI -0.45 to 0.38, two studies, n = 279 women, I2 = 61%, low-quality evidence). It was not
possible to include one of the trials in the meta-analyses; this trial compared three groups: exercise plus soy milk, soy milk only and
control; results favoured exercise relative to the comparators, but study numbers were small. One trial compared exercise with HT, and
the HT group reported significantly fewer flushes in 24 hours than the exercise group (mean difference 5.8, 95% CI 3.17 to 8.43, 14
participants). None of the trials found evidence of a difference between groups with respect to adverse effects, but data were very scanty.
Authors’ conclusions
Evidence was insufficient to show whether exercise is an effective treatment for vasomotor menopausal symptoms. One small study
suggested that HT is more effective than exercise. Evidence was insufficient to show the relative effectiveness of exercise when compared
with HT or yoga.
P L A I N L A N G U A G E S U M M A R Y
Exercise for vasomotor menopausal symptoms
Review question: Is exercise an effective treatment for reducing hot flushes/night sweats in menopausal women with hot flushes?
Background: Studies suggest that a high proportion of menopausal women will experience hot flushes and night sweats. Hormone
therapy is considered to be the most effective treatment for symptoms. However, studies have reported that hormone therapies are
potentially associated with some negative health effects; many women are now choosing not to use these and are looking for alternatives.
Therefore, it is increasingly important to identify lifestyle modifications that may help to reduce the frequency and severity of hot
flushes and night sweats. Review authors from The Cochrane Collaboration examined the evidence, which is current to March 2014.
Study characteristics: Five studies randomly assigned 762 women experiencing hot flushes/night sweats. Three trials and two trials,
respectively, were included in pooled comparisons of exercise versus control (n = 454 women) and exercise versus yoga (n = 279 women).
One small study (14 women) compared exercise versus hormone therapy.
Key findings: When exercise was compared with no intervention, no evidence was found of any difference in their effect on hot
flushes. One small study suggested that HT is more effective than exercise. Evidence was insufficient to show whether exercise was
more effective than yoga. None of the trials found any evidence of differences between groups with respect to adverse effects, but data
were very scanty.
Quality of the evidence: The methodological quality of the studies was variable. We assessed the evidence as of low quality: The main
limitations were poor reporting of study methods, inconsistent results and lack of precision.
2Exercise for vasomotor menopausal symptoms (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Exercise versus control for vasomotor menopausal symptoms
Population: women with vasomotor menopausal symptoms
Setting: university
Intervention: exercise versus no active treatment
Outcomes Illustrative comparative
risks* (95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Exercise versus no ac-
tive treatment
Change in hot flushes/
night sweats
Self-report1
Follow-up: 3 to 24
months
Mean change in hot
flushes/night sweats is
0.10 standard deviations
lower in the exercise
groups
(-0.33 lower to 0.13
higher)
454
(3 studies)
⊕©©©
Lowa,b,c
SMD -0.10 (-0.33 to 0.
13)
*The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
aEvidence self-reported: validated scales or logs/diaries used.
bRecruitment, method of determining menopausal status and characteristics of included women varied.
cVariation in the direction of effect.
B A C K G R O U N D
Description of the condition
Menopause is a significant event in most women’s lives, as it marks
the end of natural reproductive life. The perimenopausal and early
postmenopausal period is typically characterised by fluctuating
levels of endogenous oestrogen, which can give rise to symptoms
that are severe and disruptive. Evidence suggests that a high pro-
portion of perimenopausal and early postmenopausal women will
experience some menopausal symptoms; hot flushes are common
(Greendale 1999). Large cultural differences are apparent in the
experience of vasomotor symptoms; women living in Western
industrialised countries are more likely to experience these than
other populations of women (Gold 2004; Reed 2013).Hot flushes
(called hot flashes in USA) occur as a sudden feeling of heat in
the face, neck and chest (WHO 1996). Hot flushes are frequently
accompanied by skin flushing and perspiration; a chill may follow
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as core body temperature drops (Greendale 1999). Hot flushes
can be occasional or frequent, can last a few seconds to an hour,
may be spontaneous and unpredictable and can vary in severity
(Freeman 1995). Hot flushes that occur during the night are typ-
ically referred to as night sweats. Flushes and night sweats are of
concern in themselves, but they also can disrupt sleep patterns
and alter daily activities, which can lead to fatigue and decreased
quality of life (NAMS 2002). Hot flushes are thought to result
from the brain’s response to diminished hormones and hormonal
fluctuations that occur during the menopause transition, which
in turn leads to instability of thermoregulatory mechanisms that
regulate temperature homeostasis in the hypothalamus (Freeman
2001).
Hormone therapy (HT) (oestrogen or combined oestrogen-pro-
gestogen therapy) is the most common treatment for hot flushes;
the North American Menopause Society (NAMS 2012) supports
its use in treating moderate to severe vasomotor symptoms. How-
ever, apparent benefits of HT have been questioned in the past
decade because trials (Hulley 1998; Viscoli 2001; WHI 2002)
failed to demonstrate thatHT is associated with secondary preven-
tion of cardiovascular disease. These publications raised concerns
about the risks and benefits of HT. Several other trials and obser-
vational studies (Holmberg 2004; Million Women Study 2003;
Rossouw 2002) have reported that HT may be linked with in-
creased risk of certain diseases, including breast cancer. Whilst the
reanalysis (Rossouw 2007) of the Women’s Health Initiative in
2007 provided evidence of coronary heart safety for users of HT
younger than 60 years of age and within 10 years of the onset of
menopause, previous uncertainty surrounding actual cost/benefit
to be gained has left many women reluctant to take HT. Doc-
tors are more cautious about prescribing HT, as demonstrated by
the large reduction in prescriptions in recent years (Hersh 2004;
Lawton 2003). In addition, evidence (Hope 1998) has suggested
that some women report adverse effects when taking HT, which
may preclude hormone use, and not all women are able to use HT.
Consequently, many women are seeking alternatives (Daley 2006;
Nelson 2005; Posadzki 2013), and it has become increasingly im-
portant to identify other evidence-based interventions that have
the potential to reduce vasomotor and other menopausal symp-
toms.
Description of the intervention
Numerous studies and reviews (Daley 2008; DH 2011; Eriksen
2004) involving other populations have reported that physical ac-
tivity and exercise participationmay have positive effects on a range
of other menopause-related symptoms and health outcomes such
as cognitive functioning, depression, sleep patterns, fatigue, bone
density, weight maintenance and cardiovascular disease. Thus, it is
reasonable to investigate whether exercise will have an impact on
menopausal vasomotor symptoms. In addition to providing signif-
icant physiological benefits (e.g. cardiovascular and bone health),
exercise may represent one of the promising alternatives to HT
and, if it is demonstrated to be effective in the treatment of vaso-
motor symptoms, offers an inexpensive intervention that typically
has few known side effects. The Royal College of Obstetricians
and Gynaecologists (RCOG 2006) in the United Kingdom (UK)
has advised (Scientific Advisory Committee Opinion Paper 6) that
women who are more active tend to suffer less from the symp-
toms of menopause, and that the best type of activity is aerobic,
sustained, regular exercise such as swimming and running.
Observational studies have reported inconsistent findings regard-
ing the association between exercise and lower rates of vasomo-
tor symptoms, although larger studies have tended to report pos-
itive associations, and smaller studies negative or no associations.
Among women attending menopause clinics in Italy (n = 66,501),
severe vasomotor symptoms were significantly more common in
those reporting lower levels of regular physical activity (Progetto
Study 2005). A similar association was found in a study of a multi-
racial population of women (N = 12,245) (Gold 2000). A low va-
somotor symptom scorewas found tobe correlatedwith regular ex-
ercise and regular free-time activities (n = 4504) (Stadberg 2000).
A recent longitudinal study (13-year follow-up) has reported that
exercise participation was associated with shorter symptom dura-
tion (Col 2009), but the sample was small (n = 205). Other smaller
observational studies (typically n < 1500) have reported negative
or no associations (Daley 2007a; Sternfeld 1999; Wilbur 1992),
but these smaller studies generally have not considered relevant
confounding variables.
Although large observational studies have indicated that exercise
might be a useful intervention in helping to ameliorate vasomotor
symptoms, these findings must be substantiated in randomised
controlled trials (RCTs). In 2011 the Cochrane review titles “Ex-
ercise for theManagement of Vasomotor Menopausal Symptoms”
included six studies that were generally small. Thus, no conclu-
sions regarding the effectiveness of exercise as a treatment for va-
somotor symptoms could be made by review authors at that time.
How the intervention might work
Plausible biological mechanisms are known by which exercise
could reduce vasomotor and other menopausal symptoms. It has
been hypothesised that endorphin concentrations in the hypotha-
lamus decrease as oestrogen production declines, enhancing the
release of norepinephrine and serotonin. Exercise may have a sim-
ilar effect to HT in the amelioration of vasomotor symptoms by
increasing hypothalamic and peripheral β-endorphin production
(Bortz 1981). In addition, evidence suggests that as endorphins
increase, the frequency and amplitude of luteinising hormone de-
crease, and this regulates gonadotropin-releasing hormone levels
(Reid 1981). Research (Heitkamp 1996) has shown that active
individuals have higher basal levels of β-endorphins than those
who are inactive. Through these mechanisms, exercise may help
to stabilise the thermoregulatory centre and diminish the risk of
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hot flushes. It has also been suggested that exercise can improve
mental health outcomes by providing a distraction or ‘time out’
strategy from daily worries (Bahrke 1978), and that exercise can
enhance feelings of accomplishment among individuals, thereby
improving self-esteem (Fox 2000).
Why it is important to do this review
If shown to be effective, exercise might be an acceptable, low-
cost, non-pharmacological treatment for vasomotor menopausal
symptoms and an alternative to HT. Exercise may confer addi-
tional physical and mental health benefits (e.g. improve cardio-
vascular and bone health, decrease feelings of depression) for per-
imenopausal and early postmenopausal women.
O B J E C T I V E S
To examine the effectiveness of any type of exercise intervention
in the management of vasomotor symptoms in symptomatic per-
imenopausal and postmenopausal women.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) were eligible for inclusion.
Cross-over trials were eligible for inclusion, but only data from the
first phase were included in meta-analyses.
Types of participants
Studies of women with surgical or spontaneous menopause, in
the perimenopausal or postmenopausal period, experiencing any
vasomotor symptoms at baseline and recruited from any setting
or population-based sample were eligible for inclusion.
Perimenopausal women were defined as women with spontaneous
menopause who had experienced irregular menstruation within
the previous 12 months. Postmenopausal women were defined as
womenwith surgical or spontaneousmenopause and amenorrhoea
for longer than 12 months.
Women experiencing vasomotor symptoms due to breast cancer
treatment and women taking any hormone therapy for any reason
before the time of study entry were excluded.
Types of interventions
Exercise was defined as structured exercise and/or physical activity
achieved through active living. Trials that compared any type of
exercise intervention with no active treatment or with other treat-
ments were included.
Active treatments used as controls could include hormone therapy
(HT), dietary supplementation, health education and alternative
forms of exercise (e.g. yoga, tai chi). When trials compared more
than one form of exercise, the intervention was as defined by the
study author.
In cases in which the study author did not define the intervention,
the less aerobically vigorous form of exercise was deemed the con-
trol comparator.
Co-interventions could include instruction in lifestyle/health ed-
ucation or health and exercise awareness and complementary and
alternative medicine.
Any dosage or duration of intervention was included.
No restriction was placed on who delivered the intervention (i.e.
researchers, primary health practitioners, physical activity profes-
sionals, health promotion agencies and medical doctors).
Interventions not involving exercise were excluded.
Types of outcome measures
• Vasomotor symptoms assessed by any method. Vasomotor
symptoms were defined as hot flushes and/or night sweats. If
more than one assessment of vasomotor symptoms was included,
preference was given to the primary outcome if this was
specified. If this was not specified, validated assessments were
preferred over unvalidated assessments.
• Individual symptoms, for example, severity or frequency, or
both, of hot flushes and night sweats.
Primary outcomes
• Effectiveness: frequency or intensity of vasomotor
menopausal symptoms.
Secondary outcomes
• Any adverse effects of exercise interventions.
Search methods for identification of studies
We searched for all published andunpublishedRCTsof exercise for
vasomotor menopausal symptoms, without language restriction
and in consultation with theMenstrual Disorders and Subfertility
Group (MDSG) Trials Search Co-ordinator.
Searches for this review were first conducted in 2006 (between 1
and 2 June 2006). Searches for the first update of this review were
conducted between 17 and 22 June 2009, and again between 16
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and 24 March 2010. For this second update, searches were con-
ducted on 3 March 2014. Searches were based on text words and
index terms, when available, encompassing vasomotor symptoms,
hot flushes, hot flashes, night sweats, nocturnal sweats, exercise,
physical activity, physical training, yoga, tai chi, walking, running,
jogging, swimming and cycling.
Electronic searches
Searches of the following electronic bibliographic databases
were performed to identify RCTs: Cochrane Central Register
of Controlled Trials (CENTRAL), MEDLINE, EMBASE and
PsycINFO. Science Citation Index and Social Science Citation
Index, Cumulative Index to Nursing and Allied Health Literature
(CINAHL) and SPORTDiscus databases were searched for previ-
ous versions of this review, but not in this update.
The Cochrane Menstrual Disorders and Subfertility Group Spe-
cialised Trials Register was not searched in the first version of this
review but was searched in both updates (16 March 2010 and 3
March 2014) and will be included in future updates. The search
string for this register can be found in Appendix 1.
Search strategies can be found in Appendix 2.
Information about ongoing trials and recently completed research
studies was obtained by searching Current Controlled Trials,
ClinicalTrials.gov and UK Clinical Research Network Portfolio
Database. A series of searches (3 March 2014) were performed us-
ing the following terms: flush, flushes, flash, flashes, sweats, sweat-
ing, nocturnal sweats, menopause.
Searching other resources
Handsearches of relevant journals and published conference ab-
stractswere performed.The following journalswere handsearched:
Medicine and Science in Sport and Exercise, Maturitas, Menopause,
Health Psychology, Journal of Women’s Health, Women and Health,
Obstetrics and Gynecology, Sports Medicine, British Journal of Ob-
stetrics and Gynaecology and American Journal of Obstetrics and Gy-
necology.
Citation lists of relevant publications, review articles and included
studies were also searched.
Data collection and analysis
Data collection and analysis were conducted in accordance with
recommendations provided in the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011).
Selection of studies
Marian Showell (Trials Search Co-ordinator for the Cochrane
Menstrual Disorders and Subfertility Group) and review authors
conducted the electronic searches for this 2014 update. Two re-
view authors (AD, AT) independently selected reports potentially
fulfilling the inclusion criteria of this review on the basis of ti-
tle and abstract. Full articles of any possibly relevant reports were
retrieved for more detailed evaluation. Both review authors then
independently performed a final selection of trials to be included
in the review by using a standardised form (eligibility form plus
instruction sheet for assessing eligibility that was designed for this
review). Reports were excluded according to the first criterion that
they failed to fulfil. Disagreements were resolved by consensus.
The principal author of the study was contacted by a review author
(AD) when additional information about the trial was needed for
a decision regarding the eligibility of reports.
Data extraction and management
For this 2014 update, data were independently extracted by two
review authors (AD, AT) using a data extraction form designed by
the review authors. When disagreements could not be resolved by
consensus, a third review author (HSL) was consulted to resolve
discrepancies. Additional information on trial methodology, par-
ticipants and study results was sought from the first or correspond-
ing author of some studies that appeared to meet the eligibility
criteria. This occurred when aspects of methodology were unclear,
when data were provided in a form unsuitable for meta-analysis or
when the vasomotor symptom status of participants was unclear.
When studies were followed by multiple publications, the main
trial report was used as the reference and was supplemented by
additional details from secondary papers.
Assessment of risk of bias in included studies
The included studies were assessed for risk of bias using the
Cochrane risk of bias assessment tool to assess sequence genera-
tion; allocation concealment; blinding of participants, providers
and outcome assessors; completeness of outcome data; selective
outcome reporting; and other potential sources of bias. All review
authors independently assessed these six domains, with disagree-
ments resolved by consensus discussion. Results are presented in
risk of bias tables for each included study.
Measures of treatment effect
For continuous data, mean differences between treatment groups
were calculated if all studies reported exactly the same outcomes.
If similar outcomes were reported on different scales, the stan-
dardised mean difference was used. Ordinal data were treated as
continuous data.
A random-effects approach was used to calculate summary effect
measures, as a priori it was expected that analyses would have
heterogeneous results.
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For dichotomous data, the numbers of events in the control and
intervention groups of each study were used to calculate Peto odds
ratios.
Confidence intervals (95%) were presented for all outcomes and
comparisons.
Unit of analysis issues
Weplanned to include all cluster-randomised trials in the analyses,
along with individually randomised trials. We adjusted sample
sizes or standard errors using the methods set out in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011). If
both cluster-randomised trials and individually randomised trials
were included, we planned to synthesise relevant information. We
considered it reasonable to combine the results from both when
little heterogeneity was noted between study designs, and when
interaction between effects of the intervention and choice of the
randomisation unit was considered unlikely.
In cross-over trials, we planned to include only data from the first
phase in the meta-analysis.
Dealing with missing data
As far as possible, data were reported using an intention-to-treat
analysis, and attempts were made to obtain missing data from the
original investigators.
Assessment of heterogeneity
Heterogeneity was considered by the review authors when clinical
and methodological characteristics of included studies were simi-
lar enough for a meta-analysis to yield a meaningful summary. Sta-
tistical analyses were performed in accordance with the guidelines
for statistical analysis developed by The Cochrane Collaboration
(Higgins 2011). Heterogeneity between the results of different
studies was assessed by the I2 statistic (a quantity that describes
approximately the proportion of variation in point estimates that
is due to heterogeneity rather than sampling error), which can be
interpreted in these broad terms.
• 0% to 40%: might not be important.
• 30% to 60%: represents moderate heterogeneity.
• 50% to 90%: represents substantial heterogeneity.
• 75% to 100%: represents considerable heterogeneity
(Higgins 2011).
Assessment of reporting biases
The review authors aimed to minimise the potential impact of re-
porting bias by ensuring a comprehensive search for eligible stud-
ies and by staying alert for duplication of data. It was planned that
a funnel plot would be prepared if 10 or more studies were identi-
fied. However, too few studies were identified for construction of
a funnel plot.
Data synthesis
When possible, data from included studies were combined using
random-effects models in the following comparisons.
• Exercise versus inactive control.
• Exercise versus yoga.
• Exercise versus HT.
Subgroup analysis and investigation of heterogeneity
Data permitting, subgroup analyses were performed to determine
separate evidence for the following.
• Perimenopausal women.
• Postmenopausal women.
• Different co-interventions.
• Intervention duration (up to 6 months vs 6 months or
longer).
Sensitivity analysis
We conducted a sensitivity analysis for the primary outcomes to
determine whether review conclusions would have differed if el-
igibility were restricted to studies at low risk of bias (i.e. studies
not deemed at high risk of bias in any domain and reporting ac-
ceptable methods of randomisation and allocation concealment).
Overall quality of the body of evidence: ’Summary of
findings’ table
We prepared a ’Summary of findings’ table using Guideline De-
velopment Tool software. This table evaluated the overall quality
of the body of evidence for the primary review outcome using
GRADE (Grades of Recommendation, Assessment, Development
and Evaluation) criteria (study limitations (i.e. risk of bias), con-
sistency of effect, imprecision, indirectness and publication bias).
R E S U L T S
Description of studies
Results of the search
In the 2007 version of this review, through a comprehensive litera-
ture search, 655 potentially relevant references were identified and
screened for retrieval. A total of 603 references were excluded on
the basis of title and abstract, and 52 references were retrieved for
more detailed evaluation. Of these, and after further scrutiny, 33
publications were not considered suitable for inclusion in the re-
view, as they were commentaries, observational studies or reviews,
7Exercise for vasomotor menopausal symptoms (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
and 18 publications initially considered eligible on the basis of
information contained in the abstract were subsequently excluded
after the full study report had been evaluated (see below). Thus,
one study (Lindh-Åstrand 2004) was eligible for inclusion in the
2007 version of this review (see Included studies section below).
For the first update of the review (2011), a further 557 poten-
tially relevant references were identified and screened for retrieval.
A total of 513 references were excluded on the basis of title and
abstract, and 44 references were retrieved for more detailed eval-
uation. Of these, and after further scrutiny, 24 publications were
not considered suitable for inclusion in the review, as they were
commentaries, observational studies or reviews, and 12 publica-
tions initially considered eligible on the basis of information con-
tained in the abstract were subsequently excluded after the full
study report had been evaluated (see below). Thus an additional
eight reports (five studies: Bergström 2005; Chatta 2008; Elavsky
2007; Hanachi 2008; Moriyama 2008) were identified as eligible,
meaning that a grand total of six studies (nine reports) were eligi-
ble for inclusion.
For this second update of the review (2014), a further 1878 po-
tentially relevant references were identified by the searches, and 27
were screened for retrieval. A total of nine references were excluded
on the basis of title and abstract, and 18 references were retrieved
for more detailed evaluation. Of these, and after further scrutiny,
two publications were not considered suitable for inclusion in the
review, as they were commentaries, observational studies or re-
views, and 14 publications initially considered eligible on the ba-
sis of information contained in the abstract were subsequently ex-
cluded after the full study report had been evaluated (see below).
Therefore two studies were eligible for inclusion (Luoto 2012;
Sternfeld 2014). For details of study screening and selection, see
Figure 1.
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Figure 1. Study flow diagram.
9Exercise for vasomotor menopausal symptoms (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
In this second update of the review (2014), on the advice of the
Cochrane Review Group and peer reviewers, three previously in-
cluded studies (Bergström 2005; Chatta 2008; Moriyama 2008)
have been excluded from further updates. Whilst the authors of
these three studies had provided data on women who were symp-
tomatic at baseline, it was believed important for future updates
to adhere to clear criteria of including only studies in which all
women were symptomatic at baseline.
Therefore a grand total of five studies (nine reports) were eligible
for inclusion in this 2014 update (Elavsky 2007; Hanachi 2008;
Lindh-Åstrand 2004; Luoto 2012; Sternfeld 2014). The Elavsky
2007 study has one additional report (Elavsky 2009), the Luoto
2012 study has two additional reports (Mannsikkamaki 2012;
Moilanen 2012) and the Sternfeld 2014 study has one additional
report (Newton 2013) relevant to this review. Full descriptions
of the included studies can be found under Characteristics of
included studies.
Study design
All included trials were parallel-group randomised controlled trials
(RCTs). They took place in Iran (Hanachi 2008), Sweden (Lindh-
Åstrand 2004), USA (Elavsky 2007; Sternfeld 2014) and Finland
(Luoto 2012). All studies appeared to be single-centre, except one
(Sternfeld 2014).
Use of intention-to-treat analysiswas clearly specified in three trials
(Elavsky 2007; Luoto 2012; Sternfeld 2014).
Two studies stated that power calculations were used to statistically
estimate the sample size (Luoto 2012; Sternfeld 2014).
Participants
The five included studies randomly assigned a total of 762 per-
imenopausal or postmenopausal women. Four trials (Hanachi
2008; Lindh-Åstrand 2004; Luoto 2012; Sternfeld 2014) deter-
mined menopausal status by measuring serum follicle-stimulating
hormone levels and serum oestradiol levels. One trial determined
menopausal status by examining self-reported bleeding patterns
(Elavsky 2007). This trial reported that premenopausal women
were also included in the sample (n = 17%), as determined by self-
reported bleeding patterns. However, contact with study authors
revealed that the bleeding history of women who initially reported
no signs of the menopause transition based on bleeding criteria
was verified before their entry into the trial (Elavsky 2007). All
trials required that women were not using any hormone treatment
(HT) at baseline.
All studies included only participants who were vasomotor symp-
tomatic at baseline.Only two trials specified the length of time par-
ticipants had been experiencing vasomotor symptoms before base-
line. One trial (Elavsky 2007) recruited women who had been ex-
periencing vasomotor symptoms in the last month before baseline,
and another (Lindh-Åstrand 2004) recruited participants who had
been vasomotor symptomatic for at least six months previously.
In one trial (Sternfeld 2014), the frequency and bothersomeness
of participants’ vasomotor symptoms were measured before ran-
domisation.
Four studies included women who were sedentary or had low ac-
tivity at baseline (Elavsky 2007; Lindh-Åstrand 2004; Luoto 2012;
Sternfeld 2014). One study excluded women who had been prac-
ticing yoga before baseline (Sternfeld 2014). One study did not
state the baseline exercise levels of participants (Hanachi 2008).
In three trials (Elavsky 2007; Luoto 2012; Sternfeld 2014), partic-
ipants were recruited after they responded to newspaper advertise-
ments or to othermedia.One trial (Lindh-Åstrand 2004) recruited
participants through a combination of newspaper advertisements
and via gynaecology outpatient clinics. One study did not report
the method used to recruit participants (Hanachi 2008).
Four trials (Elavsky 2007; Lindh-Åstrand 2004; Luoto 2012;
Sternfeld 2014) reported generally comparable group demo-
graphic characteristics at baseline. One trial (Hanachi 2008) did
not report the demographic characteristics of groups at baseline.
Interventions
Comparisons were as follows.
• Exercise (walking) versus yoga versus no intervention
(Elavsky 2007).
• Exercise (aerobics) versus HT (Lindh-Åstrand 2004).
• Exercise (walking) plus soy milk consumption versus soy
milk consumption only versus no intervention (Hanachi 2008).
• Exercise (cardiovascular conditioning) versus yoga versus
usual activity, plus omega-3 or placebo pills in a 1:1 ratio within
each group (Sternfeld 2014).
• Exercise (walking) versus controls, plus lectures once or
twice per month on physical activity and general health in both
arms (Luoto 2012).
Length of the interventions ranged from three (Hanachi 2008;
Lindh-Åstrand 2004; Sternfeld 2014) to four (Elavsky 2007) to
six months (Luoto 2012). Only two trials provided data on com-
pliance with the intervention(s) (Elavsky 2007; Sternfeld 2014).
Outcomes
Vasomotor symptoms
All studies assessed vasomotor symptoms by self-report. One trial
(Luoto 2012) assessed vasomotor symptoms by using more than
one questionnaire/measure, but only one of the measures had
been validated (the vasomotor symptoms subscale of theWomen’s
HealthQuestionnaire).One study (Elavsky 2007) used theGreene
Climacteric Scale (Greene 1998). Two studies (Hanachi 2008;
Lindh-Åstrand 2004) used the Kupperman Index (Kupperman
1959), although one study (Lindh-Åstrand 2004) did not report
data specifically from the vasomotor symptoms subscale. Two stud-
ies (Lindh-Åstrand 2004; Luoto 2012) used a log/diary to assess
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the number and/or severity of hot flushes at baseline and at follow-
up.
Adverse events
One study (Sternfeld 2014) assessed adverse events.
Data extraction
Data from all trials, except one (Hanachi 2008), were entered
into the meta-analysis. One study produced binary data (Hanachi
2008), and four studies produced continuous data (Elavsky 2007;
Lindh-Åstrand 2004; Luoto 2012; Sternfeld 2014). One study in-
cluded both continuous (primary outcome) and binary data (sec-
ondary outcome). In the meta-analyses, we used data from the
final follow-up, regardless of time since baseline.
Length of follow-up varied considerably between studies, ranging
from three months (Hanachi 2008; Sternfeld 2014) to six months
(Luoto 2012) to nine months (Lindh-Åstrand 2004) to 24months
(Elavsky 2007).
Excluded studies
In 2007, on the basis of information provided in the abstract,
one study was not traceable by the British Library (Pangaotopulos
2004) despite numerous search attempts. Eight reports were not
RCTs (Hammar 1990; Kemmler 2004; Salmone 1998; Slaven
1994; Wallace 1982; Weltman 1982; Ueda 2000; Ueda 2004).
Eight reports did not include women who were symptomatic at
baseline (Aiello 2004; Boraz 2001; Hunter 1999; Krasnoff 1996;
Liao 1998; Polis 1989; Steele 1997;Wilbur 2005); we were unable
to obtain data for women in these trials who were symptomatic,
and we were unable to reach the trial authors or the authors were
unable to provide data in a usable form for this review. For further
details, see the Characteristics of excluded studies tables.
Further studies were identified as ineligible during the process of
updating the 2011 review (first update). Five reports were not
RCTs (Booth-LaForce 2007; Cohen 2006; Elavsky 2005; Lee
2009; McAndrew 2009), four reports did not include vasomotor
symptomatic women at baseline (Asbury 2006; Gonzalez 2009;
Maesta 2007; Villaverde 2006b), one report did not include an
exercise intervention (Welty 2007) and one report did not include
a measure of vasomotor symptoms (O’Donnell 2009).
In this 2014 update of the review, a further 15 studies were re-
trieved and excluded for the following reasons: duplicate abstract
of another study (Cramer 2012b); nomeasure of vasomotor symp-
toms (Foster-Schubert 2012; Kline 2012; Kok 2005; Lee 2012;
Riesco 2012; Villaverde-Gutiérrez 2012); unclear whether partic-
ipants were vasomotor symptomatic at baseline (Llaneza 2011;
Riesco 2011); participants were not vasomotor symptomatic at
baseline (Alfonso 2012; Joshi 2011; Ogwumike 2011); trials were
not RCTs (Garcia 2011); and participants were taking HT at base-
line (Huang 2010; Moreira 2012). As discussed earlier, in this sec-
ond update of the review (2014), it was decided that the studies
by Bergström 2005, Chatta 2008 and Moriyama 2008 that had
been included in the 2010 review should be excluded from any
subsequent updates, including this one, as not all randomly as-
signed participants were symptomatic at baseline.
Risk of bias in included studies
For further details, refer to the methodological quality summary
(Figure 2) and the methodological quality graph (Figure 3).
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 3. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Allocation
Three studies reported adequate methods of sequence generation (
Elavsky 2007; Luoto 2012; Sternfeld 2014). They used computer-
generated lists. Two trials did not specify this information and
were rated as having unclear risk in this domain (Hanachi 2008;
Lindh-Åstrand 2004).
Two studies provided evidence of adequate allocation concealment
(Lindh-Åstrand 2004; Sternfeld 2014); presealed envelopes, iden-
tical opaque sealed envelopes or a secure Web-based database was
used. Two studies provided insufficient information as to whether
allocation was concealed and were rated as having unclear risk
in this domain (Hanachi 2008; Luoto 2012). Contact with the
trial authors revealed that allocation was not concealed in one trial
(Elavsky 2007); this study was rated as having high risk of bias in
this domain.
Blinding
Evaluation of exercise-based treatment is more difficult than eval-
uation of other types of treatment such as pharmacological inter-
ventions because usually neither the participant nor the intervener
can be blinded to participants’ allocation; comments here should
be interpreted in light of these constraints. Two trials clearly stated
that outcome assessors were blinded to group allocation and were
rated as having low risk of bias in this domain (Elavsky 2007;
Sternfeld 2014). The other studies were rated as having unclear
risk of bias.
Incomplete outcome data
Two trials adequately addressed this domain and were rated as
having low risk of bias (Elavsky 2007; Sternfeld 2014). One trial
had a high attrition rate and was rated as having high risk of
bias (Lindh-Åstrand 2004), and in two trials, the risk of bias was
unclear (Hanachi 2008; Luoto 2012). Please see Characteristics of
included studies for details.
Selective reporting
Only one trial reported adverse events (Sternfeld 2014) and was
rated as having low risk of bias in this domain. The other studies
were rated as having unclear risk of selective reporting bias.
Other potential sources of bias
No other potential source of bias was identified for two trials
(Luoto 2012; Sternfeld 2014), which were rated as having low risk
in this domain. Three trials were rated as having unclear risk of bias
in this domain as a result of lack of baseline equivalence between
groups (Elavsky 2007), poor reporting (Hanachi 2008) or high
rates of cross-over between treatment arms (Lindh-Åstrand 2004).
Effects of interventions
See: Summary of findings for the main comparison Exercise
versus control for vasomotor menopausal symptoms; Summary
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of findings 2 Exercise versus yoga for vasomotor menopausal
symptoms
Threemeta-analyseswere conducted: exercise versus no treatment/
control, exercise versus yoga and exercise versus HT. In the five in-
cluded studies, a total of 762 participants were randomly assigned,
but data from one study (Hanachi 2008) (n = 37) could not be
included in any meta-analysis. Therefore data from 725 randomly
assigned participants were eligible for inclusion in the meta-anal-
yses, and of these, 605 provided follow-up data (83.4%).
1 Exercise versus no treatment/control
Four trials were eligible for inclusion in the comparison of exercise
versus no treatment or a control condition.
Three studies compared exercise (walking (Elavsky 2007), aero-
bic exercise (Luoto 2012) and cardiovascular training (Sternfeld
2014)) versus no intervention. A fourth study (Hanachi 2008)
compared exercise plus soy milk versus soy milk alone or a control
condition (not described). No direct comparison was performed
between the two intervention groups.
Primary outcome
1.1 Frequency or intensity of vasomotor menopausal
symptoms
When three studies were pooled (Elavsky 2007; Luoto 2012;
Sternfeld 2014), no evidence suggested a difference between
groups (standardised mean difference (SMD) -0.10, 95% confi-
dence interval (CI) -0.33 to 0.13, 454 participants, I2 = 30%, low-
quality evidence) (Figure 4 Analysis 1.1). Hanachi 2008 reported
data unsuitable for pooling. Thirty-seven women were included
in the analysis. The study authors stated that hot flush scores de-
creased significantly during the treatment period in the exercise
plus soy milk group and in the soy milk only group, relative to the
control group (P value < 0.05). See Analysis 1.2 for details.
Figure 4. Forest plot of comparison. Exercise versus control, outcome: 1.1 Change in hot flushes/night
sweats.
Secondary outcomes
1.2 Adverse effects of the intervention
The number of incident adverse events was reported in one trial
(Sternfeld 2014) and was similar in both groups (17% for exercise
and 18% for usual activity); no serious adverse events related to
the study occurred in either group.
2 Exercise versus yoga
Two studies were included in this analysis (Figure 5 Analysis
2.1). These trials compared exercise (walking) (Elavsky 2007) and
cardiovascular training (Sternfeld 2014) versus yoga.
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Figure 5. Forest plot of comparison. Exercise versus yoga, outcome: 1.2 Change in hot flushes/night sweats.
Primary outcome
2.1 Frequency or intensity of vasomotor menopausal
symptoms
When the two studies were pooled, no evidence showed a dif-
ference between groups (SMD 0.03, 95% CI -0.45 to 0.38, 279
participants, I2 = 61%, low-quality evidence).
Secondary outcomes
2.2 Adverse effects of the intervention
No serious adverse events were reported for either group.
3 Exercise versus hormone therapy (HT)
One trial compared exercise (aerobics) versus HT (Lindh-Åstrand
2004).
Primary outcome
3.1 Frequency or intensity of vasomotor menopausal
symptoms
In this trial (Lindh-Åstrand 2004) at 12 weeks’ follow-up, a larger
reduction in frequency of hot flushes per 24 hours was seen in the
HT group than in the exercise group (mean difference 5.80, 95%
CI 3.17 to 8.43, 14 participants) (Figure 6; Analysis 3.1).
Figure 6. Forest plot of comparison. 3 Exercise versus HT, outcome: 3.1 Change in mean number of flushes
in 24 hours.
Secondary outcomes
3.2 Adverse effects of the intervention
Data on adverse effects of the intervention were not reported in
the only trial included in this comparison.
Sensitivity analyses
Only one study was deemed to have low risk of bias (Sternfeld
2014). Exclusion from analysis of other studies did not affect our
overall findings for any outcome.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Exercise versus yoga for vasomotor menopausal symptoms
Population: women with vasomotor menopausal symptoms
Intervention: exercise versus yoga
Outcomes Illustrative comparative
risks* (95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Corresponding risk
Exercise versus yoga
Change in hot flushes/
night sweats
Self-report
Follow-up: 3 to 4 months
Mean change in hot
flushes/night sweats
0.03 standard deviations
lower in the exercise
groups
(-0.45 lower to 0.38
higher)
279
(2 studies)
⊕©©©
Lowa,b,c
SMD -0.03 (-0.45 to 0.
38)
*The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
aEvidence self-reported: validated scales or logs/diaries used.
bRecruitment, method of determining menopausal status and characteristics of included women varied.
cVariation in the direction of effect (I2 = 61%).
D I S C U S S I O N
Summary of main results
Evidence was insufficient to show whether exercise is an effective
treatment for vasomotor menopausal symptoms. Evidence was
also insufficient to reveal the relative effectiveness of exercise when
compared with HT or yoga. The evidence was of low quality
because of observed limitations in study design, inconsistency and
imprecision.
The two largest trials to date (Luoto 2012; Sternfeld 2014) showed
no significant differences between exercise and control groups for
their primary outcome of vasomotor symptoms. These results
should also be considered in the context of intervention contam-
ination, which is often a problem with exercise trials, as com-
parator/usual care groups may spontaneously choose to exercise,
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thereby diluting the effect. This issue might have been a particular
problem in one of the larger included trials (Luoto 2012), inwhich
the control group was given lectures on physical activity, thus pro-
viding encouragement for them to exercise. Although the RCOG
(RCOG 2006) has advised that regular aerobic exercise may help
relieve menopausal symptoms, the most common of which is hot
flushes, current evidence does not support this statement. Addi-
tional high-quality trials are required before conclusions can be
drawn about the effectiveness of exercise compared with no treat-
ment or active interventions such as yoga or HT. Evidence of het-
erogeneity is also apparent in the meta-analysis of exercise versus
yoga, highlighting further the need for additional research.
Overall completeness and applicability of
evidence
Data regarding adverse effects of exercise interventions are insuf-
ficient, and not all studies reported data in a form that could be
included in the meta-analysis.
Quality of the evidence
The methodological quality of studies was variable, and only one
trial (Sternfeld 2014) was at low risk of bias. In the comparisons
of exercise versus control/no treatment, 30% heterogeneity was
evident, whereas in the comparison of exercise versus yoga, hetero-
geneity was high (61%), possibly because of differences between
studies in intensity of the interventions.
Sample sizes in both meta-analyses were relatively small. Some
study authors did not follow the CONSORT (Consolidated Stan-
dards of Reporting Trials) guidelines in reporting their studies;
this often made it difficult for review authors to extract and inter-
pret the information required for this review. Studies also varied
considerably by type and duration of the exercise intervention and
length of follow-up.
We assessed the evidence as low quality: Limitations in study de-
sign, inconsistency and imprecision were noted. Methods of re-
cruitment and of determining menopausal status varied, as did
characteristics of included women. Evidence was self-reported on
a variety of validated scales or logs/diaries. Both meta-analyses
showed variation in the direction of effect.
Potential biases in the review process
Publication and selection biases are potential threats to all system-
atic reviews. We believe that all relevant studies have been identi-
fied but cannot rule out the possibility that additional trials may be
unpublished or published in sources not accessible to our search.
Agreements and disagreements with other
studies or reviews
We are not aware of any other published reviews of randomised
controlled trials that have assessed the effectiveness of exercise as
a treatment for vasomotor menopausal symptoms.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Evidence was insufficient to show whether exercise is an effective
treatment for vasomotor menopausal symptoms. Evidence was
also insufficient to reveal the relative effectiveness of exercise and
yoga. One small study suggested that HT is more effective than
exercise.
Implications for research
Additional high-quality trials of exercise versus no exercise or in
comparison with other types of interventions would be welcome.
Studies should evaluate not just the outcomes of frequency and
intensity of vasomotor symptoms, but also whether adverse events
are associated with exercise. Cost/benefit analyses should be in-
cluded. Adherence has not been detailed in reports or has not
been reported in sufficient detail to show how much exercise
women were performing throughout the interventions. Future tri-
als should measure and report adherence in greater detail.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Elavsky 2007
Methods 3-group RCT: exercise, yoga, control
Participants Low active or sedentary women 42 to 58 years of age who were experiencing vasomotor
menopausal symptoms in the past month and had no history of surgical menopause and
no hormone therapy use in the previous 6 months
A total of 164 participants were randomly assigned (exercise n = 63, yoga n = 62,
control n = 39). At four-month follow-up, 16 were lost to follow-up (exercise n = 6,
yoga n = 7, control n = 3). However, only 1 participant (yoga group) was excluded
from the analyses (used HT); thus 163 participants were included in the analyses (161
for primary outcome). At 2-year follow-up, data were available for 134/164 randomly
assigned participants. Of these, 102/134 agreed to take part in the 2-year follow-up
study and 99/134 returned a follow-up questionnaire (response rate of 74%; 99/134)
(exercise n = 41, yoga n = 35, control n = 23). Overall, 60.4% (99/164) provided follow-
up questionnaire data 2 years after randomisation
Interventions • The exercise intervention involved a low to moderate supervised walking
programme. Participants met 3 times per week for 1 hour at a university centre.
Participants were also encouraged to add 1 to 2 days of exercise outside of the
supervised programme. Participants received individualised exercise prescriptions, as
well as educational leaflets, handouts and newsletters
• The yoga (Iyengar) group met twice per week for 90 minutes. Sessions were
supervised by an instructor. Iyengar yoga places particular emphasis on developing
strength, stamina, flexibility and balance, as well as concentration and meditation.
Participants were also encouraged to practice postures outside of the supervised
programme, following handouts received on a weekly basis
• Wait list control
The intervention period was 4 months
Outcomes Vasomotor menopausal symptoms using the Greene Climacteric Scale. Adverse events
were not reported
Notes Inclusion criteria stipulated that women had to be vasomotor symptomatic at baseline,
but results indicate that based on classification of bleeding patterns (by self-report), 17%
of participants would be considered premenopausal
Most of the sample (70%) were overweight or obese
More participants were purposefully randomly assigned to the exercise (n = 63) and
yoga (n = 62) groups than to the control group (n = 39). Trial authors intentionally
oversampled in the exercise and control groups to increase the probability of detecting a
difference between outcomes in these groups, and because resources for physician cover
for physiological testing were limited in the control group
Intervention compliance: Compliance between yoga (63%) and exercise (70%) groups
did not differ significantly during the 4-month intervention period. At 2-year follow-
up, physical activity was assessed in terms of energy expenditure/METs per week, but no
data according to group were reported
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Elavsky 2007 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned to trial
groups by a computer-based statistical package
Allocation concealment (selection bias) High risk Contact with trial authors indicates that alloca-
tion was not concealed from the research team
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It is not possible to blind exercise interventions
to participants nor to trial personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study states that all medical and testing staff
were blind to group allocation at outcome as-
sessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk 161/164 women were analysed for the primary
outcome
Selective reporting (reporting bias) Unclear risk Study does not report adverse events
Other bias Unclear risk Trial groups were not balanced at baseline with
regard to age, socioeconomic status and number
of children. High rate of refusal to participate
among eligible women (204/462 refused) could
potentially affect applicability of findings
Hanachi 2008
Methods 3-group RCT: exercise plus soy milk (n = 12 analysed), soy milk only (n = 15 analysed)
and control (n = 10 analysed)
Study authors analysed 37 participants (exercise plus soy milk n = 12; soy milk only n =
15; control n = 10), but no data regarding dropouts or loss to follow-up were reported.
Study authors did not respond to our request for further information regarding loss to
follow-up. Therefore it is unclear how many women were randomly assigned
Participants Non-smoking postmenopausal women, free from disease, not taking any form of hor-
mone treatment in the previous 12 months and not currently using soybean-derived
products or herbal medications, with intact uterus and experiencing hot flushes
Interventions • Exercise intervention involved 1 hour of walking each day + soy milk
• Soy milk only
• Control (intervention not described)
Outcomes Vasomotor menopausal symptoms assessed using the Kupperman Index. Adverse events
not reported
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Hanachi 2008 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study states it is a randomised trial and pro-
vides no other details
Allocation concealment (selection bias) Unclear risk No informationwas given in the trial report
to allow a judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It is not possible to blind exercise interven-
tions to participants or to trial personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Reports of the trial do not state whether
outcome assessors were blinded from
knowledge of which intervention partici-
pants received
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear whether the 37 women anal-
ysed included all who were randomly as-
signed
Selective reporting (reporting bias) Unclear risk Outcomes were reported in narrative form
andongraphs; no rawdatawere suitable for
analysis. Adverse events were not reported
Other bias Unclear risk Poor reporting: Control intervention was
not described. Baseline characteristics are
similar in the 2 groups
Lindh-Åstrand 2004
Methods 2-group RCT: exercise, HT
Participants Women 48 to 63 years, with vasomotor symptoms and spontaneous menopause at least
6 months previously and exercising less than 1 hour per week at baseline. Contact with
the study author revealed that participants were not taking HT at baseline
Study originally included 75 women who were randomly assigned to exercise, 2 modes
of acupuncture, oestrogen therapy (HT) or applied relaxation (n = 15 per group). We
describe data here from the report that compared exercise with HT (Lindh-Åstrand
2004). Results from the other groups are presented elsewhere (Nedstrand 2005; Wyon
2004), but none of these are compared with exercise. Of women randomly assigned
to exercise, 4/15 did not start the exercise programme, and 1 participant dropped out
during the intervention, resulting in 10/15 receiving follow-up at 12 weeks. Only 5
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Lindh-Åstrand 2004 (Continued)
of the participants randomly assigned to exercise completed follow-up at 24 week and
36 weeks. Among women randomly assigned to HT (n = 15), all completed follow-up
at 12 weeks, and 9/15 completed 24-week follow-up. It is not entirely clear from the
report how many women in the HT completed follow-up at 9 months, but it appears
to be 9/15. In summary, 14 participants provided follow-up data at 24 weeks; therefore
the Lindh-Åstrand 2004 trial was judged likely to contain high attrition bias because
dropout at follow-up was substantial
Interventions • Exercise group participated in 60-minute aerobic classes of moderate intensity at a
university centre for 12 weeks. Women had to attend at least 2 classes every week and
to spend at least 1 additional hour/wk participating in exercise of such intensity that a
shower was required afterwards
• HT group was given unopposed 17β-oestradiol 2 mg orally per day for 12 weeks.
Thereafter it was suggested that they continue their oestrogen treatment with
additional sequential progestogens given monthly
Outcomes Number of hot flushes per 24 hours using a diary/log book. Climacteric symptoms
assessed by the Kupperman Index, although scores for vasomotor symptoms subscale
were not reported
Total climacteric symptom intensity and distress experienced from symptoms, although
this outcome was not vasomotor symptom specific and was focused on all menopausal
symptoms
Notes This trial report is part of a larger trial in which women were also randomly assigned to
3 other treatment groups; data from these groups are reported separately
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study reports it is a randomised trial and provides no
other details
Allocation concealment (selection bias) Low risk Randomisation was performed with the use of identical,
opaque, sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It is not possible to blind exercise interventions to partic-
ipants or to trial personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Reports of the trial do not state whether outcome asses-
sors were blinded from knowledge of which intervention
participants received
Incomplete outcome data (attrition bias)
All outcomes
High risk Data are incomplete for all outcomes and were unbal-
anced across groups at each follow-up. Reason for miss-
ing data is likely to be related to true outcome. Only 10/
15 (66%) women in exercise arm were included in the
analysis
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Lindh-Åstrand 2004 (Continued)
Selective reporting (reporting bias) Unclear risk Adverse effects were not reported
Other bias Unclear risk High rate of cross-overs was seen in the exercise arm-
only 5 women completed protocol and follow-up; 5/10
included in analysis started HT during study
Luoto 2012
Methods 2-group RCT: exercise vs control
Participants Symptomatic women experiencing daily hot flushes, 40 to 63 years of age, not taken
HT in the previous 3 months, sedentary and 6 to 36 months since less menstruation.
All participants were of white ethnicity
Study randomly assigned 176 women equally to the exercise group or the control group;
154 received follow-up (exercise group n = 74; control group n = 80). Both trial groups
received 1-hour lectures once or twice per month from the principal investigator on
physical activity and general health
Interventions • Six-month unsupervised aerobic exercise training programme that included
aerobic training 4 times per week for 50 minutes at moderate to hard intensity. At least
2 sessions per week needed to include walking or nordic walking
• Women in the control group were asked (via questionnaire on paper) once in the
middle of the trial (11-12 weeks from baseline) whether they had changed any of their
physical activities or dietary habits
All participants also attended lectures (60-75 minutes) once or twice per month, which
covered topics such as physical activity and general health
Outcomes Vasomotor symptoms measured by theWomen’s Health Questionnaire. Hot flushes and
night sweats recorded by diary. Adverse events not reported
Notes Control group attended lectures once or twice per month, which covered topics such as
physical activity and general health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list was computer generated
Allocation concealment (selection bias) Unclear risk Envelopes were used to randomly assign partici-
pants, but no details were provided about whether
they were sealed or consecutively numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information about blinding is given
27Exercise for vasomotor menopausal symptoms (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Luoto 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information about blinding is given
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 154/176 (88%) women were included in the anal-
ysis. Dropouts were potentially related to efficacy
or adverse effects (e.g. 2 dropouts in exercise group
crossed over to HT, 2 dropped out because of mus-
culoskeletal problems, no reason was given for 9).
Significant differences in age and weight were noted
between dropouts and non-dropouts
Selective reporting (reporting bias) Unclear risk Adverse effects were not reported
Other bias Low risk This study appears free of other sources of bias
Sternfeld 2014
Methods 3-group RCT: exercise, yoga and usual care control group
Participants Women 42 to 62 years of age, late perimenopausal or postmenopausal or having a
hysterectomywith FSH>20mlU/mL and oestradiol≥ 50 pg/mL. To be eligible, women
must have been experiencing 14 or more vasomotor symptoms per week in each of 3
consecutive weeks, as measured by daily diaries. Vasomotor symptom frequency between
visits 1 and 2 no less than 50% of weekly mean in the 2 weeks before Visit 1, and
symptoms rated as severe or bothersome on at least 4 occasions. Women taking HT or
contraceptives in past 2 months were excluded, as were women with BMI > 37. Women
taking omega-3 and participating in yoga in the previous 3 months were excluded
355 women were randomly assigned to exercise (n = 106), usual activity (n = 142) or
yoga (n = 107). Of these, 338 received follow-up (exercise n = 101, yoga n = 102, control
group n = 135)
Interventions • Exercise intervention consisted of 12 weeks of 3 individualised cardiovascular
training sessions per week at a local leisure centre supervised by an exercise trainer. The
intervention was progressive over time, from moderate to hard intensity. Sessions lasted
between 40 and 60 minutes
• Usual activity: This group was asked to refrain from changing physical activity
behaviour during the trial
• The yoga intervention involved the practice of cooling breathing exercises and 3
groups of poses (asanas). Poses were sequenced according to the principles of viniyoga
to promote safety
Women were further randomly assigned (1:1) within each arm to 1.8 g/d U-3 fish oil or
identically appearing placebo capsules
Outcomes Vasomotor symptom frequency as measured by daily diaries. Bother of symptoms as
measured by daily diaries. Adverse events reported for both groups
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Sternfeld 2014 (Continued)
Notes This was a multi-site trial. Data for the yoga group were extracted for this review from
the second trial publication (Newton 2013)
Intervention compliance: Participants attended 8.5 (3.5) (mean (SD)) of 12 scheduled
yoga sessions (ranging from 0 to 13). Women practiced at home 4.1 (2.3) times per
week. On average, women did poses 2.6 (1.1) times per week and Yoga Nidra 2.3 (1.
2) times per week. Adherence to the exercise intervention was assessed in several ways:
attendance at 80% or more of training sessions; achievement of 80% or more of weekly
energy expenditure goal; and achievement of target heart rate (+10 beats/min) for 50%
or more of exercise time. Documented home-based training sessions were counted for
women who were unable to attend a facility-based session. Study authors reported that
74women adhered to the intervention (defined by training sessions), 66 women achieved
the energy expenditure goal and 75 achieved the target heart rate goal. Activity behaviour
outside exercise training decreased by 1.5 steps/min in the exercise group compared with
an increase of 0.22 steps/min in the usual activity group (P value 0.02)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated dynamic randomisa-
tion algorithm was used to maintain com-
parability between groups
Allocation concealment (selection bias) Low risk Randomisation was conducted using a se-
cure Web-based database
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Data collectors were blinded to partici-
pants’ group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Local access to information on group as-
signment was limited to site staff involved
in delivery of the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk 241/248 (97%) women in exercise vs usual
care group and 237/249 in yoga vs usual
care group (95%)were included in the anal-
ysis
Selective reporting (reporting bias) Low risk Report includes all expected outcomes and
data on adverse events
Other bias Low risk Womenwere further randomly assigned (1:
1) within each arm to 1.8 g/d U-3 fish oil
or identically appearing placebo capsules.
This appears unlikely to be associated with
bias
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aiello 2004 Not all participants were symptomatic at baseline
Alfonso 2012 Participants were not vasomotor symptomatic at baseline
Asbury 2006 Participants were not vasomotor symptomatic at baseline
Bergström 2005 Not all participants were symptomatic at baseline
Booth-LaForce 2007 Not an RCT
Boraz 2001 Not all participants were vasomotor symptomatic at baseline
Chatta 2008 Not all participants were symptomatic at baseline
Cohen 2006 Not an RCT
Cramer 2012b Nor an RCT
Elavsky 2005 Not an RCT
Foster-Schubert 2012 No measure of vasomotor symptoms
Garcia 2011 Not an RCT
Gonzalez 2009 Participants were not vasomotor symptomatic at baseline
Hammar 1990 Case control study
Huang 2010 12.3% of participants were taking HT at baseline. Not possible to obtain data for those participants not
taking HT at baseline
Hunter 1999 29% of participants were taking HT at the time of the study. Not clear whether all participants were
vasomotor symptomatic at baseline
Joshi 2011 Participants were not vasomotor symptomatic at baseline
Kemmler 2004 Not an RCT
Kline 2012 No measure of vasomotor symptoms
Kok 2005 No measure of vasomotor symptoms
Krasnoff 1996 Not clear whether all participants were symptomatic at baseline, and the study author could not be
located for clarification
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(Continued)
Lee 2009 Not an RCT (systematic review)
Lee 2012 No measure of vasomotor symptoms
Liao 1998 Not all participants were symptomatic at baseline
Llaneza 2011 Unclear whether participants were symptomatic at baseline
Maesta 2007 Participants were not vasomotor symptomatic at baseline
McAndrew 2009 Not an RCT
Moreira 2012 Most participants were taking HT at baseline
Moriyama 2008 Not all participants were symptomatic at baseline
O’Donnell 2009 No measure of vasomotor symptoms
Ogwumike 2011 Participants were not vasomotor symptomatic at baseline
Pangaotopulos 2004 Study not traceable by the British Library
Polis 1989 Not all participants were symptomatic at baseline
Riesco 2011 Unclear whether participants were symptomatic at baseline
Riesco 2012 No measure of vasomotor symptoms
Salmone 1998 Not an RCT
Slaven 1994 Not an RCT
Steele 1997 Not all participants were symptomatic at baseline
Ueda 2000 Not an RCT
Ueda 2004 Not an RCT
Villaverde 2006b Participants were not vasomotor symptomatic at baseline
Villaverde-Gutiérrez 2012 No measure of vasomotor symptoms
Wallace 1982 Not an RCT
Weltman 1982 Not an RCT
Welty 2007 Did not include an exercise intervention
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(Continued)
Wilbur 2005 Not all participants were symptomatic at baseline
Characteristics of ongoing studies [ordered by study ID]
Daley 2013
Trial name or title Aerobic exercise as a treatment for vasomotor menopausal symptoms: randomised controlled trial
Methods RCT
Participants 261 inactive perimenopausal and menopausal symptomatic women not using HT
Interventions 2 exercise interventions: (1) exercise consultations plus DVD and written literature; (2) exercise consultations
plus exercise social support groups
Outcomes Hot flushes, night sweats, other menopausal symptoms, quality of life, depression, anxiety
Starting date January 2012
Contact information a.daley@bham.ac.uk
Notes Principal investigator of this trial is also the first author of this review
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D A T A A N D A N A L Y S E S
Comparison 1. Exercise versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in hot flushes/night
sweats
3 454 Std. Mean Difference (IV, Random, 95% CI) -0.10 [-0.33, 0.13]
2 Additional data: decrease in hot
flushes
Other data No numeric data
Comparison 2. Exercise versus yoga
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in hot flushes/night
sweats
2 279 Std. Mean Difference (IV, Random, 95% CI) -0.03 [-0.45, 0.38]
Comparison 3. Exercise versus HT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in mean number of
flushes in 24 hours
1 14 Mean Difference (IV, Random, 95% CI) 5.80 [3.17, 8.43]
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Analysis 1.1. Comparison 1 Exercise versus control, Outcome 1 Change in hot flushes/night sweats.
Review: Exercise for vasomotor menopausal symptoms
Comparison: 1 Exercise versus control
Outcome: 1 Change in hot flushes/night sweats
Study or subgroup Exercise Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Elavsky 2007 (1) 41 -0.65 (1.49) 23 -0.07 (1.29) 17.2 % -0.40 [ -0.92, 0.11 ]
Luoto 2012 (2) 74 -0.1 (0.37) 80 -0.05 (0.25) 36.2 % -0.16 [ -0.48, 0.16 ]
Sternfeld 2014 (3) 101 -2.4 (3.32) 135 -2.6 (3.54) 46.7 % 0.06 [ -0.20, 0.32 ]
Total (95% CI) 216 238 100.0 % -0.10 [ -0.33, 0.13 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.84, df = 2 (P = 0.24); I2 =30%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours exercise Favours control
(1) Controls received no active treatment
(2) Both arms attended a course of lectures. Controls had no other active intervention.
(3) Control was usual activity. Week 12 compared to baseline.
Analysis 1.2. Comparison 1 Exercise versus control, Outcome 2 Additional data: decrease in hot flushes.
Additional data: decrease in hot flushes
Study Outcome Intervention Comparison Result Statistical
significance
Hanachi 2008 Decrease in hot
flushes
1. Exercise + soymilk 2. Soymilk only
3. Control (no de-
tails)
Group 1. Hot flushes
decreased by 83%
relative to Group 3
Group 2. Hot flushes
decreased by 72%
relative to Group 3
Significant
benefit for Group 1
and Group 2 versus
Group 3 p<0.05
34Exercise for vasomotor menopausal symptoms (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Exercise versus yoga, Outcome 1 Change in hot flushes/night sweats.
Review: Exercise for vasomotor menopausal symptoms
Comparison: 2 Exercise versus yoga
Outcome: 1 Change in hot flushes/night sweats
Study or subgroup Exercise yoga
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Elavsky 2007 41 -0.65 (1.49) 35 -0.22 (1.47) 40.9 % -0.29 [ -0.74, 0.17 ]
Sternfeld 2014 (1) 101 -2.4 (3.32) 102 -2.9 (3.61) 59.1 % 0.14 [ -0.13, 0.42 ]
Total (95% CI) 142 137 100.0 % -0.03 [ -0.45, 0.38 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 2.53, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours exercise Favours yoga
(1) Data for Yoga group are from second trial publication, Newton 2013
Analysis 3.1. Comparison 3 Exercise versus HT, Outcome 1 Change in mean number of flushes in 24 hours.
Review: Exercise for vasomotor menopausal symptoms
Comparison: 3 Exercise versus HT
Outcome: 1 Change in mean number of flushes in 24 hours
Study or subgroup Exercise HT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Lindh- strand 2004 5 -1.9 (2.3) 9 -7.7 (2.59) 100.0 % 5.80 [ 3.17, 8.43 ]
Total (95% CI) 5 9 100.0 % 5.80 [ 3.17, 8.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.32 (P = 0.000016)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours exercise Favours HT
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A P P E N D I C E S
Appendix 1. MDSG search strategy
MDSG search string last searched 03.04.14
Keywords CONTAINS “vasomotor” or “vasomotor symptoms” or “hot flashes” or “hot flushes” or “night sweats” or “night sweats-
outcome” or “Flushes” or “Flushing” or “flushing outcome” or “climacteric ”or “climacteric symptoms” or “climacteric symptoms-
outcome” or “climacteric symptoms - vasomotor” or “menopausal symptoms” or “*Menopause” or “ Title CONTAINS” vasomotor“
or ”vasomotor symptoms“ or ”hot flashes“ or ”hot flushes“ or ”night sweats“ or ”night sweats-outcome“ or ”Flushes“ or ”Flushing“
or ”flushing outcome“ or ”climacteric “ or ”climacteric symptoms“ or ”climacteric symptoms-outcome“ or ”climacteric symptoms -
vasomotor“ or ”menopausal symptoms“ or”*Menopause“
AND
Keywords CONTAINS ”exercise“ or ”Exercise Therapy“ or ”yoga“ or ”walking“ or ”aerobic exercise“ or Title CONTAINS ”exercise“
or ”Exercise Therapy“ or ”yoga“ or ”walking“ or ”aerobic exercise“
Appendix 2. Search strategies
Database: PsycINFO <1806 to February Week 4 2014>
Search strategy:
1 exp Physical Education/ (3154)
2 exp Physical Fitness/ (3030)
3 exp Exercise/ or exp Aerobic Exercise/ (16253)
4 (physical$ or training or exercise$).tw. (393121)
5 (yoga or tai chi or tai ji or walking or running or jogging or swimming or cycling or bicycling).tw. (29621)
6 exp Yoga/ (954)
7 exp Walking/ (3224)
8 exp Running/ (1394)
9 exp Swimming/ (1348)
10 aerobic.tw. (2587)
11 fitness.tw. (10692)
12 or/1-11 (421747)
13 (flush$ or flash$ or sweat$ or vasomotor).tw. (10418)
14 exp Menopause/ (2863)
15 (menopaus$ or perimenopaus$ or postmenopaus$).tw. (4881)
16 climacter$.tw. (441)
17 or/13-16 (15055)
18 12 and 17 (2048)
19 random.tw. (39815)
20 control.tw. (309344)
21 double-blind.tw. (17649)
22 clinical trials/ (7328)
23 placebo/ (3706)
24 exp Treatment/ (570434)
25 or/19-24 (870514)
26 18 and 25 (747)
27 limit 26 to yr=”2013 -Current“ (39)
Database: EMBASE <1980 to 2014 Week 09>
Search strategy:
1 exp physical education/ (10109)
2 exp training/ (58544)
3 (physical$ or training or exercise$).tw. (979676)
4 exp fitness/ (27677)
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5 exp exercise/ or exp aerobic exercise/ or exp stretching exercise/ (205535)
6 (yoga or tai chi or tai ji or walking or running or jogging or swimming or cycling or bicycling).tw. (157806)
7 exp yoga/ (3683)
8 exp Tai Chi/ (1354)
9 exp walking/ (60510)
10 exp running/ (15401)
11 exp swimming/ (14918)
12 exp bicycle/ (6032)
13 aerobic.tw. (64048)
14 fitness.tw. (45085)
15 or/1-14 (1265195)
16 (flush$ or flash$ or sweat$ or vasomotor).tw. (75639)
17 exp hot flush/ (11365)
18 exp flushing/ (13004)
19 (menopaus$ or perimenopaus$ or postmenopaus$).tw. (90733)
20 exp climacterium/ (7176)
21 exp menopause/ or exp menopause related disorder/ or exp ”menopause and climacterium“/ (99278)
22 exp early menopause/ (1561)
23 exp postmenopause/ (44450)
24 climacter$.tw. (4791)
25 vasomotor.tw. (12406)
26 or/16-25 (207997)
27 15 and 26 (18964)
28 Clinical Trial/ (893833)
29 Randomized Controlled Trial/ (368808)
30 exp randomization/ (65021)
31 Single Blind Procedure/ (19116)
32 Double Blind Procedure/ (120876)
33 Crossover Procedure/ (40108)
34 Placebo/ (236677)
35 Randomi?ed controlled trial$.tw. (101620)
36 Rct.tw. (13868)
37 random allocation.tw. (1346)
38 randomly allocated.tw. (20579)
39 allocated randomly.tw. (1963)
40 (allocated adj2 random).tw. (745)
41 Single blind$.tw. (14514)
42 Double blind$.tw. (145091)
43 ((treble or triple) adj blind$).tw. (362)
44 placebo$.tw. (203019)
45 prospective study/ (266200)
46 or/28-45 (1422423)
47 case study/ (24405)
48 case report.tw. (263308)
49 abstract report/ or letter/ (907127)
50 or/47-49 (1189158)
51 46 not 50 (1384398)
52 27 and 51 (3959)
53 (2013$ or 2014$).em. (1884971)
54 (2013$ or 2014$).dp. (212803)
55 53 or 54 (1885690)
56 52 and 55 (410)
Database: EBM Reviews-Cochrane Central Register of Controlled Trials <January 2014>
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Search strategy:
1 exp ”Physical Education and Training“/ (1277)
2 (physical$ or training or exercise$).tw. (61997)
3 exp physical fitness/ (1836)
4 exp exercise/ (11692)
5 (yoga or tai chi or tai ji or walking or running or jogging or swimming or cycling or bicycling).tw. (9870)
6 exp yoga/ (214)
7 exp tai ji/ (133)
8 exp walking/ (2124)
9 exp running/ (1112)
10 exp jogging/ (36)
11 exp swimming/ (304)
12 exp bicycling/ (896)
13 aerobic.tw. (4058)
14 fitness.tw. (2416)
15 or/1-14 (68074)
16 (flush$ or flash$ or sweat$ or vasomotor).tw. (4227)
17 exp hot flashes/ (457)
18 exp flushing/ (139)
19 exp climacteric/ (5514)
20 (menopaus$ or perimenopaus$ or postmenopaus$).tw. (10946)
21 exp menopause/ or exp menopause, premature/ or exp perimenopause/ or exp postmenopause/ (5295)
22 climacter$.tw. (630)
23 or/16-22 (15173)
24 15 and 23 (1499)
25 limit 24 to yr=”2013 -Current“ (70)
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
<1946 to Present>
Search strategy:
1 exp ”Physical Education and Training“/ (13245)
2 (physical$ or training or exercise$).tw. (779516)
3 exp physical fitness/ (21299)
4 exp exercise/ (114797)
5 (yoga or tai chi or tai ji or walking or running or jogging or swimming or cycling or bicycling).tw. (131512)
6 exp yoga/ (1442)
7 exp tai ji/ (563)
8 exp walking/ (18971)
9 exp running/ (13258)
10 exp jogging/ (694)
11 exp swimming/ (18217)
12 exp bicycling/ (7443)
13 aerobic.tw. (53530)
14 fitness.tw. (38743)
15 or/1-14 (973082)
16 (flush$ or flash$ or sweat$ or vasomotor).tw. (61572)
17 exp hot flashes/ (2230)
18 exp flushing/ (1051)
19 exp climacteric/ (48213)
20 (menopaus$ or perimenopaus$ or postmenopaus$).tw. (66942)
21 exp menopause/ or exp menopause, premature/ or exp perimenopause/ or exp postmenopause/ (44796)
22 climacter$.tw. (3954)
23 or/16-22 (140049)
24 randomized controlled trial.pt. (363966)
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25 controlled clinical trial.pt. (87650)
26 randomized.ab. (284281)
27 placebo.tw. (154362)
28 clinical trials as topic.sh. (167902)
29 randomly.ab. (206672)
30 trial.ti. (121423)
31 (crossover or cross-over or cross over).tw. (59389)
32 or/24-31 (900158)
33 exp animals/ not humans.sh. (3885146)
34 32 not 33 (829112)
35 15 and 23 and 34 (1878)
36 (2013$ or 2014$).ed. (1077600)
37 (2013$ or 2014$).dp. (1113935)
38 36 or 37 (1535052)
39 35 and 38 (208)
WH A T ’ S N E W
Last assessed as up-to-date: 3 March 2014.
Date Event Description
3 March 2014 New search has been performed Review updated
3 March 2014 New citation required but conclusions have not changed 2 new studies were added to the review (Luoto 2012;
Sternfeld 2014), and 3 previously included studies were
deemed to be ineligible and have been excluded (
Bergström 2005; Chatta 2008; Moriyama 2008), but
this did not lead to a change in conclusions
H I S T O R Y
Protocol first published: Issue 3, 2006
Review first published: Issue 4, 2007
Date Event Description
8 August 2011 New citation required and conclusions have changed Date field (’Assessed as Up-to-date’) was corrected
6 April 2011 New citation required and conclusions have changed Conclusions have changed since the review was pub-
lished in Issue 4, 2007
25 January 2011 Amended Contact details have been updated
16 March 2010 New search has been performed Updated review includes 5 new studies
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(Continued)
7 November 2008 Amended Review has been converted to new review format in this
update
15 August 2007 New citation required and conclusions have changed Substantive amendments have been made
C O N T R I B U T I O N S O F A U T H O R S
Amanda Daley: conceived of the review, co-ordinated the review, collected and managed data for the review, read the final draft and
served as guarantor of the review.
Helen Stokes-Lampard: collected and managed data for the review and read and commented on the final draft.
Chrstine MacArthur: collected data for the review and read and commented on the final draft.
Adèle Thomas: collected data for the review and read and commented on the final draft
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• University of Birmingham, UK.
Host institution of authors
External sources
• National Institute for Health Research (NIHR), UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The secondary outcomes of quality of life, tolerability and general symptomatology have been deleted and are no longer included in
this review.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Exercise; ∗Menopause; ∗Sweating; Complementary Therapies; Estrogen Replacement Therapy; Hot Flashes [∗therapy]; Randomized
Controlled Trials as Topic; Sweat Gland Diseases [∗therapy]; Walking; Yoga
MeSH check words
Female; Humans; Middle Aged
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